On the basis of previous studies, we identified pyrazine-pyridine A as a potent vascular endothelial growth factor inhibitor and pyrimidine-pyridine B as a moderately potent cyclin dependent kinase (CDK) inhibitor. A proposed combination of CGP-60474 and compound B led to the discovery of [1, 3, 5] triazine-pyridine as a new series of potent CDK inhibitors. Palladium-catalyzed CC bond formation reactions, particularly the Negishi coupling ...